{
  "id": 11486354,
  "title": "Metabolite-inspired compounds show promise for ulcerative colitis drug discovery",
  "url": "https://urgent.news/2026/10/02/metabolite-inspired-compounds-show-promise-for-ulcerative-colitis",
  "topic": "science",
  "section": "Science",
  "published": "2026-10-02T17:20:13.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-metabolite-compounds-ulcerative-colitis-drug.html"
  },
  "original_language": "en",
  "account": "Researchers from the Institute for Biomedical Sciences at Georgia State University have discovered two new compounds, MLY2 and MLY8, derived from an anti-inflammatory metabolite called M13. These compounds show promise in treating ulcerative colitis, a chronic inflammatory disease of the gastrointestinal tract that currently has limited safe and effective treatment options.\n\nIn experiments involving mice and human tissue samples, MLY2 and MLY8 demonstrated enhanced anti-inflammatory activity compared to M13. The modified compounds not only restored colon length but also reduced fecal lipocalin-2, a biomarker for intestinal inflammation. Furthermore, laboratory-cultured colon tissue samples from patients with treatment-refractory ulcerative colitis showed that MLY2 and MLY8 suppressed inflammatory cytokine production more effectively than M13.\n\nUlcerative colitis remains a significant clinical challenge due to the limited availability of safe, orally active anti-inflammatory drugs. As phase II metabolism was traditionally seen as a detoxification process, this study highlights the potential of phase II metabolites, like M13, as valuable starting points for discovering new biologically active compounds. The researchers believe that modifying the chemical structure of these metabolites could lead to the development of new anti-inflammatory drug candidates.\n\nSenior author Chunhua Yang, a research assistant professor at the Institute for Biomedical Sciences, stated that their findings open up a new avenue for drug discovery in inflammatory diseases. The research provides a foundation for further studies, suggesting that metabolites could be underutilized scaffolds for medicinal chemistry optimization in treating ulcerative colitis and other similar conditions.",
  "summary": "Two structurally modified compounds derived from an anti-inflammatory metabolite demonstrated enhanced anti-inflammatory activity in experimental ulcerative colitis in mice and human tissue, offering an underexplored drug discovery opportunity for this chronic inflammatory disease, according to a study led by researchers in the Institute for Biomedical Sciences at Georgia State University.",
  "key_points": [
    "Compounds MLY2 and MLY8 derived from metabolite M13 show promise for ulcerative colitis treatment.",
    "MLY2 and MLY8 demonstrated enhanced anti-inflammatory activity in mice and human tissue samples."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}